Andrew Schwab Sells 400,000 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 400,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the completion of the sale, the director directly owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. The trade was a 16.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

CAMP4 Therapeutics Trading Down 4.3%

Shares of NASDAQ CAMP opened at $3.79 on Wednesday. CAMP4 Therapeutics Corporation has a 12 month low of $1.41 and a 12 month high of $7.75. The firm has a market capitalization of $237.82 million, a price-to-earnings ratio of -1.63 and a beta of 0.27. The business has a 50-day moving average of $4.12 and a 200-day moving average of $4.35.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million during the quarter. On average, analysts predict that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CAMP. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Piper Sandler reissued an “overweight” rating and issued a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Finally, Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.56.

Hedge Funds Weigh In On CAMP4 Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CAMP. Bridgeway Capital Management LLC purchased a new position in CAMP4 Therapeutics in the 2nd quarter worth $36,000. Jefferies Financial Group Inc. purchased a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $70,000. Bank of America Corp DE bought a new position in shares of CAMP4 Therapeutics during the second quarter valued at about $78,000. OMERS ADMINISTRATION Corp bought a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at about $115,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of CAMP4 Therapeutics in the fourth quarter worth about $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.